Related Experiment Video
Updated: Jul 18, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Outcomes prediction for children with Hodgkin's disease]
Insights
A new prognostic score for pediatric Hodgkin's disease was developed, identifying favorable, medium, and high-risk groups. This score aids in tailoring risk-adapted therapy for improved outcomes in young patients.
Area of Science:
- Pediatric Oncology
- Clinical Research
- Biostatistics
Context:
- Hodgkin's disease is a significant malignancy in children.
- Accurate prognostic tools are crucial for effective treatment stratification.
- Previous prognostic models may not fully capture the complexity of pediatric Hodgkin's disease.
Purpose:
- To develop and validate a prognostic score for pediatric Hodgkin's disease.
- To identify key prognostic factors influencing treatment outcomes.
- To stratify patients into distinct risk groups for tailored therapy.
Summary:
- A prognostic score was developed using data from 551 pediatric patients with Hodgkin's disease (stages I-IV, 1967-2001).
- Significant factors included age (≥11 years), lymph node involvement (≥5cm), B symptoms, lymphocytic depletion histology, stage IVB/extranodal disease (E), and "b" symptoms.
- Three risk groups were identified: favorable (65.8%, OS 92%, RFS 67%), medium (17.8%, OS 67%, RFS 48%), and high (16.4%, OS 38%, RFS 25%).
Impact:
- Provides a tool for estimating risk in pediatric Hodgkin's disease.
- Facilitates the implementation of risk-adapted therapeutic strategies.
- Potential to improve survival rates and reduce treatment-related morbidity in pediatric patients.
Abstract:
A prognostic score was developed in the course of treatment of 551 pediatric patients with Hodgkin's disease stage I-IV (1967-2001). It took care of such significant factors of uni-and multivariate analysis as age (11 years or more), peripheral lymph node involvement (5cm or more), systemic symptoms (B), histological pattern for lymphocytic depletion, IVB stage and/or extranodal disease (E) and biological rate of tumor process ("b"). As a result, three groups at risk were identified: favorable prognosis (65.8%: overall survival - 92%, relapse-free - 67%), medium risk (17.8%: overall survival - 67%, relapse-free 48%) and high risk (16.4%: overall survival - 38%, relapse-free 25%). Our data may be used to estimate the scope of risk-adapted therapy for Hodgkin's disease.
